[Percutaneous coronary intervention].
The aim of this article was to provide an overview on percutaneous coronary intervention and to identify the predictive factors of the outcome. Numerous and diverse factors have been associated with interventional treatment that include intrinsic stent thrombogenicity and patient-, target lesion-, and procedure-related issues. Stent design, surface coating and the addition of adjunctive pharmacotherapeutic agents may influence the degree of platelet activation. The application of drug eluting stents represents a potential landmark event for percutaneous vascular treatment because marked reductions in restenosis and repeat revascularization rates have been observed with drug eluting stents in randomized trials. Every effort should be made to optimize stent size and deployment. Periprocedural glycoprotein IIb/IIIa inhibitors should be used for complex stent procedures and post-procedural antiplatelet therapy should be extended for at least 1 year.
Csapó
Kálmán
K
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar, Kardiológiai Intézet.
D000208:Acute Disease; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D003324:Coronary Artery Disease / Q000150:complications / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D017202:Myocardial Ischemia / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011237:Predictive Value of Tests; D012307:Risk Factors; D015607:Stents; D013577:Syndrome; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex